Comparative Pharmacology
Head-to-head clinical analysis: MICROGESTIN FE 1 20 versus MIUDELLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MICROGESTIN FE 1 20 versus MIUDELLA.
MICROGESTIN FE 1/20 vs MIUDELLA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing ethinyl estradiol (estrogen) and norethindrone acetate (progestin). Suppresses gonadotropins via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation; increases cervical mucus viscosity and alters endometrial lining.
MIUDELLA (everolimus) is an mTOR inhibitor that binds to the FKBP-12 protein to form a complex that inhibits the mTOR kinase activity, thereby reducing cell proliferation, angiogenesis, and glucose uptake.
One tablet orally once daily, containing norethindrone acetate 1 mg and ethinyl estradiol 20 mcg, taken at the same time each day for 21 days followed by 7 days of placebo (iron tablets) or continuous cycling per prescribing information.
Intravenous: 1.5 mg/kg every 12 hours for 14 days.
None Documented
None Documented
Norethindrone: 5-14 hours (mean 8 hours); Ethinyl estradiol: 12-24 hours (mean 18 hours); Steady-state in 5-7 days
Terminal elimination half-life is 18-24 hours in healthy adults; prolonged in renal impairment (up to 40 hours in severe cases).
Renal: ~50-60% as metabolites; Fecal: ~30-40% as metabolites; Biliary: minor; <1% unchanged
Primarily renal excretion of unchanged drug (85-90%); biliary/fecal elimination accounts for 5-10%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive